{"name":"TUMOR","title":"","children":[{"id":"Brain","name":"Brain","presenterLast":"Brain","children":[{"id":"3998","name":"3998","title":"Alerting the immune system by removing epigenetic silencing of Th1 chemokines","presenterFirst":"Heather","presenterLast":"Sonnemann","presenterInstitution":"NIH","keywords":"Chemokines;NA;NA;NA","target":"DNMT","tumor":"Brain","combo":null,"sage":"immune_effector","pharma":"academia"}]},{"id":"Breast","name":"Breast","presenterLast":"Breast","children":[{"id":"2993","name":"2993","title":"STING signaling in breast tumor microenvironment modulates immune checkpoint blockade efficacy in the neu-N mouse model of breast cancer","presenterFirst":"Jeremy","presenterLast":"Foote","presenterInstitution":"Johns Hopkins University, School of Medicine","keywords":"Immunotherapy;Checkpoint;Checkpoint;NA","target":"STING","tumor":"Breast","combo":null,"sage":"immune_effector","pharma":"academia"},{"id":"2660","name":"2660","title":"PD-1 blockade in combination with zoledronic acid to enhance the antitumor efficacy in the breast cancer mouse model","presenterFirst":"Zhengyu","presenterLast":"Jin","presenterInstitution":"Peking Union Medical College Hospital, Chinese Academy of Medical Sciences","keywords":"Breast cancer;Zoledronic acid;Zoledronic acid;Checkpoint inhibitior","target":"zoledronic_acid","tumor":"Breast","combo":null,"sage":"cancer_cell","pharma":"academia"},{"id":"4770","name":"4770","title":"Novel CXCR3 allosteric modulators inhibit breast cancer stem cells and metastasis","presenterFirst":"Amy","presenterLast":"Fulton","presenterInstitution":"Univ. of Maryland Greenebaum Cancer Ctr.","keywords":"Chemokine receptor;Metastasis;Metastasis;Breast cancer","target":"CXCR3","tumor":"Breast","combo":null,"sage":"immunosuppressive","pharma":"academia"},{"id":"1621","name":"1621","title":"Adoptively transferred B cells directly kill tumor cells <i>via</i> the CXCR4/CXCL12 & perforin pathways","presenterFirst":"Qiao","presenterLast":"Li","presenterInstitution":"Univ. of Michigan","keywords":"Breast cancer;B cells;B cells;CXCR4","target":"CXCR4","tumor":"Breast","combo":null,"sage":"immunosuppressive","pharma":"academia"},{"id":"2680","name":"2680","title":"A novel pro-tumorigenic role for IDO1 in inflammatory neovascularization","presenterFirst":"Alexander","presenterLast":"Muller","presenterInstitution":"Lankenau Inst. for Medical Research","keywords":"Inflammation;Metabolism;Metabolism;Metastasis","target":"IDO1","tumor":"Breast","combo":null,"sage":"immunosuppressive","pharma":"academia"},{"id":"5579","name":"5579","title":"Strategic inhibition of adenosine A2A receptor (A2AR) by CPI-444 improves CD8<sup>+</sup>:Treg ratios and enhances T-cell killing of a HER-2/neu expressing murine tumor","presenterFirst":"Blake","presenterLast":"Scott","presenterInstitution":"Johns Hopkins University School of Medicine","keywords":"Breast cancer;Small molecule inhibitor;Small molecule inhibitor;Vaccines","target":"A2AR","tumor":"Breast","combo":null,"sage":"immunosuppressive","pharma":"academia"},{"id":"1634","name":"1634","title":"CDK4/6 inhibition directly enhances an anti-tumor immune response in breast cancer","presenterFirst":"Molly","presenterLast":"DeCristo*","presenterInstitution":"Brigham and Women's Hospital","keywords":"Cyclin-dependent kinase inhibitor;Immune response;Immune response;T cell exhaustion","target":"CDK4/6","tumor":"Breast","combo":null,"sage":"immune_effector","pharma":"academia"},{"id":"607","name":"607","title":"PDL1 Expression Associated with Triple Negative Breast Ductal Carcinomas in African American Women","presenterFirst":"Farhan","presenterLast":"Khan","presenterInstitution":"Howard University Hospital","keywords":"African American;NA;NA;NA","target":"PI3K","tumor":"Breast","combo":null,"sage":"cancer_cell","pharma":"academia"},{"id":"568","name":"568","title":"Regulatory T cell recruitment limits the effectiveness of checkpoint inhibition for claudin-low breast cancer","presenterFirst":"Sarah","presenterLast":"Vick","presenterInstitution":"University of North Carolina","keywords":"Immunotherapy;NA;NA;NA","target":"CXCR4","tumor":"Breast","combo":null,"sage":"immunosuppressive","pharma":"academia"},{"id":"4854","name":"4854","title":"Evaluating HDAC6 as a causal factor in metastatic breast cancer to develop immunotherapy","presenterFirst":"Debarati","presenterLast":"Banik","presenterInstitution":"The George Washington University","keywords":"Epigenetics;Histone deacetylase inhibitor;Histone deacetylase inhibitor;NA","target":"HDAC6","tumor":"Breast","combo":null,"sage":"immune_effector","pharma":"academia"},{"id":"643","name":"643","title":"Induced MHCII expression on breast cancer cells broadens the responding T cell repertoire, delays tumor-specific T cell exhaustion, and impairs tumor growth","presenterFirst":"Tyler","presenterLast":"McCaw","presenterInstitution":"University of Alabama at Birmingham","keywords":"T cell;MHC II;MHC II;Histone deacetylase inhibitor","target":"HDAC","tumor":"Breast","combo":null,"sage":"cancer_cell","pharma":"academia"}]},{"id":"Colorectal","name":"Colorectal","presenterLast":"Colorectal","children":[{"id":"4358","name":"4358","title":"The immunomodulatory anti-cancer agent, RRx-001, induces a vaccine-like interferon response through epigenetic induction of viral mimicry","presenterFirst":"Susan","presenterLast":"Knox","presenterInstitution":"Stanford University School of Medicine","keywords":"Immunomodulation;Interferons;Interferons;NA","target":"DNMT","tumor":"Colorectal","combo":null,"sage":"immune_effector","pharma":"academia"},{"id":"630","name":"630","title":"Inactivation of DNA repair triggers dynamic neoantigen evolution and impairs cancer growth","presenterFirst":"Giovanni","presenterLast":"Germano","presenterInstitution":"Candiolo Cancer Institute","keywords":"Immune response;DNA repair;DNA repair;Colorectal cancer","target":"chemo","tumor":"Colorectal","combo":null,"sage":"cancer_cell","pharma":"academia"},{"id":"2222","name":"2222","title":"Sildenafil suppresses inflammation-driven colorectal cancer in mice.","presenterFirst":"Bianca","presenterLast":"Islam","presenterInstitution":"Augusta University, Georgia Cancer Center","keywords":"Colon cancer;Inflammation;Inflammation;Therapeutics","target":"PDE5","tumor":"Colorectal","combo":null,"sage":"immunosuppressive","pharma":"academia"},{"id":"3021","name":"3021","title":"CCR5 Inhibition: macrophage repolarization therapy for colorectal cancer","presenterFirst":"Niels","presenterLast":"Halama","presenterInstitution":"National Ctr. for Tumor Diseases","keywords":"Immunotherapy;Colorectal cancer;Colorectal cancer;Metastasis","target":"CCR5","tumor":"Colorectal","combo":null,"sage":"immunosuppressive","pharma":"academia"},{"id":"3022","name":"3022","title":"Novel Hydrocarbon Stapled Peptide inhibitors Suppresses \u03b2-catenin Dependent Cancer Growth and Immunomodulates Colorectal Tumors","presenterFirst":"David","presenterLast":"Zhu","presenterInstitution":"WntRx/Lab Central","keywords":"Wnt pathway;Immunomodulation;Immunomodulation;Colorectal cancer","target":"beta_catenin","tumor":"Colorectal","combo":null,"sage":"cancer_cell","pharma":"academia"},{"id":"LB-193","name":"LB-193","title":"Protein phosphatase 2A inhibition,with a novel small molecule inhibitor, LB-100, achieves durable immune-mediated antitumor activity when combined with PD1 blockade in a preclinical model","presenterFirst":"Winson","presenterLast":"Ho","presenterInstitution":"National Institutes of Health","keywords":"Protein phosphatase;NA;NA;NA","target":"PP2A","tumor":"Colorectal","combo":null,"sage":"immunosuppressive","pharma":"academia"}]},{"id":"Gastric","name":"Gastric","presenterLast":"Gastric","children":[{"id":"941","name":"941","title":"CXCL1-CXCR2 Signalling Might Recruit the Bone Marrow-derived Mesenchymal Cells to the Carcinoma-associated Fibroblasts of Gastric Cancer","presenterFirst":"Masakazu","presenterLast":"Yashiro","presenterInstitution":"Osaka City Univ. Grad. School of Medicine","keywords":"Stromal-epithelial interactions;Gastrointestinal cancers: stomach;Gastrointestinal cancers: stomach;CXCR2","target":"CXCR2","tumor":"Gastric","combo":null,"sage":"immunosuppressive","pharma":"academia"}]},{"id":"Glioblastoma","name":"Glioblastoma","presenterLast":"Glioblastoma","children":[{"id":"572","name":"572","title":"Inhibition of IDO1 with epacadostat enhances anti-tumor efficacy of PD-1 blockade in a syngeneic glioblastoma (GBM) model","presenterFirst":"David","presenterLast":"Reardon","presenterInstitution":"Dana-Farber Cancer Inst.","keywords":"Immunomodulation;NA;NA;NA","target":"IDO1","tumor":"Glioblastoma","combo":null,"sage":"immunosuppressive","pharma":"academia"}]},{"id":"Head_Neck","name":"Head_Neck","presenterLast":"Head_Neck","children":[{"id":"2016","name":"2016","title":"Novel dual cIAP1/XIAP antagonist ASTX660 activity in preclinical models of human papillomavirus(+) and (-) head and neck squamous cell carcinoma","presenterFirst":"Roy","presenterLast":"Xiao","presenterInstitution":"National Institutes of Health","keywords":"Head and neck cancers;IAP;IAP;Tumor necrosis factor [alpha]","target":"SMAC","tumor":"Head_Neck","combo":null,"sage":"cancer_cell","pharma":"academia"},{"id":"2637","name":"2637","title":"Anti-tumor activity of cisplatin is enhanced by PD-1 blockade in preclinical models of head and neck squamous cell carcinoma","presenterFirst":"Nicole","presenterLast":"Schmitt","presenterInstitution":"Johns Hopkins University and NIDCD","keywords":"Cisplatin;Head and neck squamous cell carcinoma;Head and neck squamous cell carcinoma;NA","target":"chemo","tumor":"Head_Neck","combo":null,"sage":"cancer_cell","pharma":"academia"},{"id":"652","name":"652","title":"PD-L1 and MHC class 1 expression levels are modulated by MEK inhibition on head and neck squamous cell carcinoma","presenterFirst":"Seong-Ho","presenterLast":"Kang","presenterInstitution":"Cancer Research Institute, Seoul National University","keywords":"Head and neck squamous cell carcinoma;HLA Class I;HLA Class I;Immunomodulation","target":"MEK","tumor":"Head_Neck","combo":null,"sage":"cancer_cell","pharma":"academia"},{"id":"95","name":"95","title":"Targeting BRD4 overcomes cetuximab resistance in HNSCC","presenterFirst":"Neil","presenterLast":"Bhola","presenterInstitution":"University of California San Francisco","keywords":"Head and neck squamous cell carcinoma cell line;cetuximab;cetuximab;Receptor tyrosine kinase","target":"BRD4","tumor":"Head_Neck","combo":null,"sage":"immunosuppressive","pharma":"academia"}]},{"id":"Hematological","name":"Hematological","presenterLast":"Hematological","children":[{"id":"960","name":"960","title":"Mechanisms underlying primary ibrutinib sensitivity in CLL","presenterFirst":"Shih-Shih","presenterLast":"Chen","presenterInstitution":"The Feinstein Institute for Medical Research","keywords":"Chronic lymphocytic leukemia;Bcl-2 protein family;Bcl-2 protein family;Drug sensitivity","target":"CXCR4","tumor":"Hematological","combo":null,"sage":"cancer_cell","pharma":"academia"}]},{"id":"Hepatocarcinoma","name":"Hepatocarcinoma","presenterLast":"Hepatocarcinoma","children":[{"id":"1636","name":"1636","title":"Increased expression of programmed death-ligand 1 (PD-L1) on infiltrating immune cells of hepatocellular carcinoma (HCC) tissues after sorafenib treatment","presenterFirst":"Li-Chun","presenterLast":"Lu","presenterInstitution":"National Taiwan Univ. Hospital","keywords":"Hepatocellular carcinoma;sorafenib;sorafenib;macrophage","target":"VEGFR","tumor":"Hepatocarcinoma","combo":null,"sage":"immune_effector","pharma":"academia"}]},{"id":"Kidney","name":"Kidney","presenterLast":"Kidney","children":[{"id":"580","name":"580","title":"Nivolumab treatment of metastatic renal cancer patients impairs Tregs and potentiates NK function: the role of CXCR4 inhibition ( \u201c REVOLUTION TRIAL\u201d).","presenterFirst":"Stefania","presenterLast":"Scala","presenterInstitution":"National Cancer Inst. Pascale","keywords":"Renal cell carcinoma;Chemokine receptor;Chemokine receptor;Immunotherapy","target":"CXCR4","tumor":"Kidney","combo":null,"sage":"immunosuppressive","pharma":"academia"}]},{"id":"Leukemia","name":"Leukemia","presenterLast":"Leukemia","children":[{"id":"2686","name":"2686","title":"Dual inhibition of BCR and TLR signaling has therapeutic potential in chronic lymphocytic leukemia","presenterFirst":"Eman","presenterLast":"Dadashian","presenterInstitution":"NIH/NHLBI","keywords":"Chronic lymphocytic leukemia;Tumor microenvironment;Tumor microenvironment;NA","target":"IRAK","tumor":"Leukemia","combo":null,"sage":"cancer_cell","pharma":"academia"}]},{"id":"Lung","name":"Lung","presenterLast":"Lung","children":[{"id":"3682","name":"3682","title":"Synergistic immunostimulatory effects and therapeutic benefit of combined histone deacetylase and bromodomain inhibition in non-small cell lung cancer","presenterFirst":"Dennis","presenterLast":"Adeegbe","presenterInstitution":"Dana Farber Cancer Institute","keywords":"Histone deacetylase inhibitor;Lung cancer non small cell;Lung cancer non small cell;Immunomodulation","target":"HDAC6","tumor":"Lung","combo":null,"sage":"immune_effector","pharma":"academia"},{"id":"5591","name":"5591","title":"Mek/erk inhibition enhances anti-pd-l1 effects on the susceptibility to NK cytotoxicity of cisplatin-resistant non-small cell lung cancer","presenterFirst":"Soo Ok","presenterLast":"Lee","presenterInstitution":"Univ. of Rochester Medical Ctr.","keywords":"Natural killer cells;Lung cancer: non-small cell;Lung cancer: non-small cell;NA","target":"MEK","tumor":"Lung","combo":null,"sage":"cancer_cell","pharma":"academia"},{"id":"621","name":"621","title":"Tumor suppressor TUSC2 immunogene therapy is synergistic with anti-PD1 in lung cancer syngeneic mouse models","presenterFirst":"Ismail","presenterLast":"Meraz","presenterInstitution":"UT MD Anderson Cancer Ctr.","keywords":"Tumor suppressor gene;Checkpoint;Checkpoint;NA","target":"TUSC2","tumor":"Lung","combo":null,"sage":"immune_effector","pharma":"academia"}]},{"id":"Lymphoma","name":"Lymphoma","presenterLast":"Lymphoma","children":[{"id":"2169","name":"2169","title":"Pharmacological modulation of CXCL12-CXCR4 intracellular trafficking potentiates the <i>in vitro</i> and <i>in vivo</i> activity of the BET bromodomain inhibitor CPI203 in diffuse large B-cell lymphoma","presenterFirst":"Clara","presenterLast":"Recasens-Zorzo","presenterInstitution":"Institut d'investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS)","keywords":"Drug synergy;CXCR4;CXCR4;c-Myc","target":"CXCR4","tumor":"Lymphoma","combo":null,"sage":"immunosuppressive","pharma":"academia"}]},{"id":"Many","name":"Many","presenterLast":"Many","children":[{"id":"2620","name":"2620","title":"Selecting the right chemotherapy partner for checkpoint inhibitors. An in vivo comparison of different drugs and dosages.","presenterFirst":"Francesco","presenterLast":"Bertolini","presenterInstitution":"European Inst. of Oncology","keywords":"Checkpoint;Immunotherapy;Immunotherapy;Vinorelbine","target":"chemo","tumor":"Many","combo":null,"sage":"immunosuppressive","pharma":"academia"},{"id":"1014","name":"1014","title":"Selective impairment of intratumoral regulatory T cells by targeting Ezh2 enhances cancer immunity","presenterFirst":"David","presenterLast":"Wang","presenterInstitution":"University of California, San Francisco","keywords":"Immunotherapy;EZH2;EZH2;TRAMP model","target":"EZH2","tumor":"Many","combo":null,"sage":"immunosuppressive","pharma":"academia"},{"id":"5662","name":"5662","title":"MEK inhibitors potentiate tumor immune surveillance by enhancing cancer cell response of IFN\u03b3","presenterFirst":"Mengyu","presenterLast":"Xie","presenterInstitution":"Moffitt Cancer Center","keywords":"MEK Inhibitor;Tumor immunity;Tumor immunity;Chemokines","target":"MEK","tumor":"Many","combo":null,"sage":"cancer_cell","pharma":"academia"},{"id":"5571","name":"5571","title":"Immune-Checkpoint Inhibition via Enzyme Mediated Degradation of Kynurenine","presenterFirst":"Todd","presenterLast":"Triplett","presenterInstitution":"University of Texas at Austin","keywords":"Immunotherapy;Tumor microenvironment;Tumor microenvironment;Checkpoint","target":"KYN","tumor":"Many","combo":null,"sage":"immunosuppressive","pharma":"academia"},{"id":"5595","name":"5595","title":"HDAC inhibitor Entinostat disrupts function of PMN-MDSC","presenterFirst":"Ayumi","presenterLast":"Hashimoto","presenterInstitution":"The Wistar Institute","keywords":"Histone deacetylase inhibitor;Immunomodulation;Immunomodulation;Immunotherapy","target":"HDAC","tumor":"Many","combo":null,"sage":"immunosuppressive","pharma":"academia"},{"id":"124","name":"124","title":"Imipridone ONC201 promotes intra-tumoral accumulation of CD3+/NK+ cells that contribute to its anti-tumor efficacy","presenterFirst":"Jessica","presenterLast":"Wagner","presenterInstitution":"Fox Chase Cancer Center","keywords":"Cancer therapy;NA;NA;NA","target":"TRAIL","tumor":"Many","combo":null,"sage":"immune_effector","pharma":"academia"},{"id":"1596","name":"1596","title":"Phase I trial of recombinant human Interleukin 15 (rhIL-15) administered as continuous intravenous infusion (CIV) for 10 days (240 hours) in patients with refractory metastatic cancers.","presenterFirst":"Kevin","presenterLast":"Conlon","presenterInstitution":"National Cancer Inst.","keywords":"Immunotherapy;NA;NA;NA","target":"IL15","tumor":"Many","combo":null,"sage":"immune_effector","pharma":"academia"},{"id":"CT091","name":"CT091","title":"Safety and pharmacodynamic activity of MEDI9197, a TLR 7/8 agonist, administered intratumorally in subjects with solid tumors","presenterFirst":"Shilpa","presenterLast":"Gupta","presenterInstitution":"Masonic Cancer Center","keywords":"Toll-like receptor 7/8 agonist;NA;NA;NA","target":"TLR7/8","tumor":"Many","combo":null,"sage":"immune_effector","pharma":"academia"},{"id":"CT116","name":"CT116","title":"BMS-986205, an optimized indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, is well tolerated with potent pharmacodynamic (PD) activity, alone and in combination with nivolumab (nivo) in advanced cancers in a phase 1/2a trial","presenterFirst":"Lillian","presenterLast":"Siu","presenterInstitution":"Princess Margaret Cancer Centre","keywords":"IDO1;BMS-986205;BMS-986205;NA","target":"IDO1","tumor":"Many","combo":null,"sage":"immunosuppressive","pharma":"academia"},{"id":"CT119","name":"CT119","title":"CPI-444, an oral adenosine A2a receptor (A2aR) antagonist, demonstrates clinical activity in patients with advanced solid tumors","presenterFirst":"Leisha","presenterLast":"Emens","presenterInstitution":"Johns Hopkins University","keywords":"Phase 1;Antitumor activity;Antitumor activity;NA","target":"A2AR","tumor":"Many","combo":null,"sage":"immunosuppressive","pharma":"academia"},{"id":"CT108","name":"CT108","title":"A phase I dose escalation study of intra-tumoral LTX-315 as monotherapy or in combination with either ipilimumab or pembrolizumab in patients with transdermally accessible tumors (NCT01986426)","presenterFirst":"Jean-Francois","presenterLast":"Baurain","presenterInstitution":"Universit\u00e9 catholique de Louvain","keywords":"Combination therapy;Peptides;Peptides;NA","target":"Other","tumor":"Many","combo":null,"sage":"immune_effector","pharma":"academia"},{"id":"CT089","name":"CT089","title":"IPI-549-01 - A Phase 1/1b, first-in-human study of IPI-549, a PI3K-\u03b3 inhibitor, as monotherapy and in combination with nivolumab in patients with advanced solid tumors","presenterFirst":"Jedd","presenterLast":"Wolchok","presenterInstitution":"Memorial Sloan Kettering Cancer Center","keywords":"checkpoint resistance;tumor microenvironment;tumor microenvironment;NA","target":"PI3K","tumor":"Many","combo":null,"sage":"immunosuppressive","pharma":"academia"},{"id":"CT117","name":"CT117","title":"Interim analysis of the Phase 2 clinical trial of the IDO pathway inhibitor indoximod in combination with pembrolizumab for patients with advanced melanoma","presenterFirst":"Yousef","presenterLast":"Zakharia","presenterInstitution":"University of Iowa","keywords":"IDO;NA;NA;NA","target":"IDO1","tumor":"Many","combo":null,"sage":"immunosuppressive","pharma":"academia"},{"id":"LB-212","name":"LB-212","title":"Antioxidant therapy reprograms macrophages from protumor M2 to antitumor M1","presenterFirst":"Brandon","presenterLast":"Griess","presenterInstitution":"Univ. of Nebraska Medical Ctr.","keywords":"Polarization;Breast cancer;Breast cancer;NA","target":"Other","tumor":"Many","combo":null,"sage":"immunosuppressive","pharma":"academia"}]},{"id":"Medulloblastoma","name":"Medulloblastoma","presenterLast":"Medulloblastoma","children":[{"id":"2004","name":"2004","title":"Epigenetic targeting of CD276 expression in medullolbastoma","presenterFirst":"Swapna","presenterLast":"Asuthkar","presenterInstitution":"University of Illinois College of Medicine at Peoria","keywords":"Medulloblastoma;Epigenetics;Epigenetics;EZH2","target":"EZH2","tumor":"Medulloblastoma","combo":null,"sage":"cancer_cell","pharma":"academia"}]},{"id":"Melanoma","name":"Melanoma","presenterLast":"Melanoma","children":[{"id":"2994","name":"2994","title":"Engineered STING targeting immunotherapy delays B16 melanoma tumor growth and significantly improves animal survival as compared to an immune-checkpoint inhibitor","presenterFirst":"Andrea","presenterLast":"Amalfitano","presenterInstitution":"Michigan State University","keywords":"Immunotherapy;AdVCA0848;AdVCA0848;STING agonist","target":"STING","tumor":"Melanoma","combo":null,"sage":"immune_effector","pharma":"academia"},{"id":"5584","name":"5584","title":"PHY906(YIV-906), an adjuvant based on a 1800-year-old Chinese medicine, enhanced the anti-tumor activity of Immune checkpoint blockade therapy: anti-PDL1, anti-PD1, anti-PD1/CTLA4 against melanoma.","presenterFirst":"Wing","presenterLast":"Lam","presenterInstitution":"Yale Univ. School of Medicine. Dept. of Pharmacology","keywords":"Immunotherapy;Adjuvant;Adjuvant;Immunomodulation","target":"Other","tumor":"Melanoma","combo":null,"sage":"immune_effector","pharma":"academia"},{"id":"1676","name":"1676","title":"EZH2 inhibitors in immunotherapy of melanoma","presenterFirst":"Peter","presenterLast":"Hersey","presenterInstitution":"Univ. of  Sydney","keywords":"melanoma;Immunomodulation;Immunomodulation;EZH2","target":"EZH2","tumor":"Melanoma","combo":null,"sage":"immune_effector","pharma":"academia"},{"id":"638","name":"638","title":"Epigenetic reprograming of immune cells through selective inhibition of HDAC6 reduces suppressive phenotypes and augments anti-tumor properties of T-cells","presenterFirst":"Andressa","presenterLast":"Sodre","presenterInstitution":"NYU Langone Medical Center","keywords":"Immunotherapy;Histone deacetylase inhibitor;Histone deacetylase inhibitor;T cell","target":"HDAC6","tumor":"Melanoma","combo":null,"sage":"immunosuppressive","pharma":"academia"},{"id":"5603","name":"5603","title":"Melanoma PD1 expression is upregulated by MAPK inhibitors leading to an immune-independent synergism with anti-PD1 antibodies","presenterFirst":"Dario","presenterLast":"Sangiolo","presenterInstitution":"University of Torino, Candiolo Cancer Institute IRCCS","keywords":"melanoma;Targeted therapy;Targeted therapy;NA","target":"MEK","tumor":"Melanoma","combo":null,"sage":"cancer_cell","pharma":"academia"},{"id":"3656","name":"3656","title":"Implication for checkpoint therapeutics: Expression of co-stimulatory and co-inhibitory molecules in melanoma cells","presenterFirst":"Rachana","presenterLast":"Maniyar","presenterInstitution":"New York Medical College","keywords":"Immunomodulation;Combination therapy;Combination therapy;Target discovery","target":"BRAF","tumor":"Melanoma","combo":null,"sage":"cancer_cell","pharma":"academia"},{"id":"3699","name":"3699","title":"Activation of NK cells cytotoxicity mediated by alveolar macrophages in the lung against murine melanoma metastases by combined aerosol immunotherapy","presenterFirst":"Michele","presenterLast":"Sommariva","presenterInstitution":"University of Milan","keywords":"Natural killer cells;Immunostimulation;Immunostimulation;Tumor metastases","target":"TLR","tumor":"Melanoma","combo":null,"sage":"immune_effector","pharma":"academia"},{"id":"1704","name":"1704","title":"UPR signaling promotes T-cell dysfunction to prevent immune-mediated cancer cell killing and immune checkpoint therapy resistance","presenterFirst":"Yismeilin","presenterLast":"Feliz Mosquea","presenterInstitution":"Wake Forest University","keywords":"Immune response;Checkpoint;Checkpoint;Immunotherapy","target":"PERK","tumor":"Melanoma","combo":null,"sage":"immune_effector","pharma":"academia"},{"id":"4976","name":"4976","title":"Ricolinostat, a selective HDAC6 inhibitor with immunomodulatory properties, has significant anti-melanoma activity in vitro and in vivo","presenterFirst":"Fengdong","presenterLast":"Cheng","presenterInstitution":"The George Washington University","keywords":"Histone deacetylase inhibitor;melanoma;melanoma;NA","target":"HDAC6","tumor":"Melanoma","combo":null,"sage":"immune_effector","pharma":"academia"},{"id":"5652","name":"5652","title":"Translational evidence of reactivated innate and adaptive immunity with intratumoral IMO-2125 in combination with systemic checkpoint inhibitors from a Phase I/II study in patients with anti-PD-1 refractory metastatic melanoma","presenterFirst":"Cara","presenterLast":"Haymaker","presenterInstitution":"UT MD Anderson Cancer Center","keywords":"Melanoma/skin cancers;cancer immunotherapy;cancer immunotherapy;Combination therapy","target":"TLR9","tumor":"Melanoma","combo":null,"sage":"immune_effector","pharma":"academia"},{"id":"3332","name":"3332","title":"Aberrant expression of CSF1R in melanoma is driven through an endogenous viral promoter and it contributes to malignant growth and the acquisition of resistance against BRAF inhibition","presenterFirst":"Orsolya","presenterLast":"Giricz","presenterInstitution":"Albert Einstein College of Medicine","keywords":"Melanoma/skin cancers;Resistance;Resistance;NA","target":"CSF1R","tumor":"Melanoma","combo":null,"sage":"immunosuppressive","pharma":"academia"},{"id":"4055","name":"4055","title":"Enhancing anti-PD-1 Immune Blockade in Melanoma through Selective Inhibition of Histone Deacetylase 6","presenterFirst":"Tessa","presenterLast":"Knox","presenterInstitution":"The George Washington University","keywords":"Histone deacetylase inhibitor;Melanoma/skin cancers;Melanoma/skin cancers;Antitumor agents","target":"HDAC6","tumor":"Melanoma","combo":null,"sage":"immune_effector","pharma":"academia"},{"id":"CT056","name":"CT056","title":"A Phase Ib/II randomised open label study of BGB324 in combination with pembrolizumab or dabrafenib/trametinib compared to pembrolizumab or dabrafenib/trametinib alone, in patients with advanced non-resectable (Stage IIIc) or metastatic (Stage IV) melanom","presenterFirst":"Oddbjorn","presenterLast":"Straume","presenterInstitution":"Haukeland Univ. Hospital","keywords":"Immunotherapy;Combination studies;Combination studies;NA","target":"AXL","tumor":"Melanoma","combo":null,"sage":"immunosuppressive","pharma":"academia"}]},{"id":"Mesothelioma","name":"Mesothelioma","presenterLast":"Mesothelioma","children":[{"id":"1633","name":"1633","title":"Immunotherapy for malignant mesothelioma that combines a mesothelia-targeted immune-activating protein and CXCL12/CXCR4 blockade","presenterFirst":"Huabiao","presenterLast":"Chen","presenterInstitution":"Massachusetts General Hospital","keywords":"Mesothelioma;CXCR4;CXCR4;Immunotherapy","target":"CXCR4","tumor":"Mesothelioma","combo":null,"sage":"immunosuppressive","pharma":"academia"}]},{"id":"Myeloma","name":"Myeloma","presenterLast":"Myeloma","children":[{"id":"5005","name":"5005","title":"Inhibition of E-selectin or E-selectin together with CXCR4 re-sensitizes multiple myeloma to treatment","presenterFirst":"Barbara","presenterLast":"Muz","presenterInstitution":"Washington University in St Louis","keywords":"Multiple myeloma;Tumor microenvironment;Tumor microenvironment;Resistance","target":"CXCR4","tumor":"Myeloma","combo":null,"sage":"immunosuppressive","pharma":"academia"},{"id":"2647","name":"2647","title":"TGF-\u03b2 type I receptor inhibitor (TEW-7197) diminishes myeloma progression by multiple immunomodulatory mechanisms in combination with ixazomib.","presenterFirst":"Byung-Gyu","presenterLast":"Kim","presenterInstitution":"Case Western Reserve University","keywords":"TGF-beta;Tumor microenvironment;Tumor microenvironment;NA","target":"TGFBR","tumor":"Myeloma","combo":null,"sage":"immunosuppressive","pharma":"academia"}]},{"id":"NA","name":"NA","presenterLast":"NA","children":[{"id":"4138","name":"4138","title":"In vitro and in vivo models for evaluation of inhibitors of tryptophan dioxygenases","presenterFirst":"Lai-Ming","presenterLast":"Ching","presenterInstitution":"Univ. of Auckland Cancer Society Res. Ctr.","keywords":"Immunomodulation;T cell;T cell;Inhibitors","target":"TDO","tumor":"NA","combo":null,"sage":"immunosuppressive","pharma":"academia"},{"id":"5799","name":"5799","title":"Targeting CX3CR1 impairs the reseeding of cancer cells recirculating from metastatic tumors.","presenterFirst":"Chen","presenterLast":"Qian","presenterInstitution":"Drexel University","keywords":"Circulating tumor cells;CX3CR1;CX3CR1;Reseeding","target":"CX3CR1","tumor":"NA","combo":null,"sage":"immunosuppressive","pharma":"academia"},{"id":"1604","name":"1604","title":"NKTR-214 synergizes with radiotherapy to drive tumor regression","presenterFirst":"Michael","presenterLast":"Mcnamara","presenterInstitution":"Earle A. Chiles Research Institute, Providence Portland Medical Ctr.","keywords":"Immunotherapy;Cytokines;Cytokines;Interleukin-2","target":"IL2","tumor":"NA","combo":null,"sage":"immune_effector","pharma":"academia"},{"id":"4338","name":"4338","title":"The role of IMPACT in survival of cancer cells during tryptophan deprivation by immunosuppressive enzyme indoleamine 2,3-dioxygenase (IDO1)","presenterFirst":"Petr","presenterLast":"Tomek","presenterInstitution":"University of Auckland","keywords":"Stress response;tryptophan deprivation;tryptophan deprivation;Bioinformatics","target":"IDO1","tumor":"NA","combo":null,"sage":"immunosuppressive","pharma":"academia"},{"id":"4005","name":"4005","title":"HDAC inhibitors regulate M2 tumor-associated macrophage function through histone acetylation","presenterFirst":"Amber","presenterLast":"de Groot","presenterInstitution":"The James Buchanan Brady Urological Institute; Johns Hopkins School of Medicine","keywords":"Macrophages;Prostate cancer;Prostate cancer;Tumor microenvironment","target":"HDAC","tumor":"NA","combo":null,"sage":"immunosuppressive","pharma":"academia"},{"id":"4704","name":"4704","title":"Long-lived de novo DNA methylation programming enforces terminal T-cell exhaustion","presenterFirst":"Hazem","presenterLast":"Ghoneim","presenterInstitution":"St. Jude Children's Research Hospital","keywords":"DNA methylation;Cancer immunotherapy;Cancer immunotherapy;Epigenetics","target":"DNMT","tumor":"NA","combo":null,"sage":"immune_effector","pharma":"academia"},{"id":"4928","name":"4928","title":"Impact of <i>E. hirae</i> on the tumoricidal activity of cyclophosphamide","presenterFirst":"Romain","presenterLast":"DAILLERE","presenterInstitution":"Gustave Roussy","keywords":"Chemotherapy;Bacterial treatment;Bacterial treatment;NA","target":"NOD2","tumor":"NA","combo":null,"sage":"immune_effector","pharma":"academia"},{"id":"5592","name":"5592","title":"Metformin improves immune function of exhausted peripheral CD8<sup>+</sup> T cells derived from cancer patients.","presenterFirst":"Mototsugu","presenterLast":"Watanabe","presenterInstitution":"Okayama University","keywords":"Immunomodulation;Metabolism;Metabolism;NA","target":"AMPK","tumor":"NA","combo":null,"sage":"immune_effector","pharma":"academia"},{"id":"3675","name":"3675","title":"Novel immune oncology strategy for targeted cytotoxic lymphocyte activation","presenterFirst":"Alexander","presenterLast":"Krupnick","presenterInstitution":"University of Virginia","keywords":"Interleukin-2;Lewis lung carcinoma;Lewis lung carcinoma;Tumor microenvironment","target":"IL2","tumor":"NA","combo":null,"sage":"immune_effector","pharma":"academia"},{"id":"4713","name":"4713","title":"Deubiquitination and stabilization of programmed cell death-ligand 1 by CSN5","presenterFirst":"Seung-Oe","presenterLast":"Lim","presenterInstitution":"UT MD Anderson Cancer Center","keywords":"Immunotherapy;Inflammation;Inflammation;CSN5","target":"CSN5","tumor":"NA","combo":null,"sage":"cancer_cell","pharma":"academia"},{"id":"4691","name":"4691","title":"Polarization of macrophages with STING agonists","presenterFirst":"Kimiora","presenterLast":"Henare","presenterInstitution":"The University of Auckland","keywords":"Macrophages;NA;NA;NA","target":"STING","tumor":"NA","combo":null,"sage":"immune_effector","pharma":"academia"}]},{"id":"Ovarian","name":"Ovarian","presenterLast":"Ovarian","children":[{"id":"788","name":"788","title":"Less is more: macrophage depletion via CSF1/CSF1R pathway improves anti-VEGF therapy after adaptive resistance","presenterFirst":"Yasmin","presenterLast":"Lyons","presenterInstitution":"University of Texas MD Anderson Cancer Center","keywords":"Macrophages;Antiangiogenic agents;Antiangiogenic agents;Resistance","target":"CSF1R","tumor":"Ovarian","combo":null,"sage":"immunosuppressive","pharma":"academia"},{"id":"947","name":"947","title":"CXCR4 in combination with immune check point inhibition in ovarian cancer mouse model demonstrates potential for novel therapeutic strategies","presenterFirst":"Kristen","presenterLast":"Starbuck","presenterInstitution":"Roswell Park Cancer Institute","keywords":"Chemokines;NA;NA;NA","target":"CXCR4","tumor":"Ovarian","combo":null,"sage":"immunosuppressive","pharma":"academia"},{"id":"956","name":"956","title":"Novel oral small molecule CXCR4 inhibitor improves activity of immune checkpoint blockade in ovarian cancer mouse model","presenterFirst":"Kristen","presenterLast":"Starbuck","presenterInstitution":"Roswell Park Cancer Institute","keywords":"Ovarian cancer;NA;NA;NA","target":"CXCR4","tumor":"Ovarian","combo":null,"sage":"immunosuppressive","pharma":"academia"}]},{"id":"Pancreatic","name":"Pancreatic","presenterLast":"Pancreatic","children":[{"id":"942","name":"942","title":"CXCR2 acts as a checkpoint regulator of the pancreatic stellate cells activity within pancreatic cancer tumor microenvironment","presenterFirst":"Mohammad","presenterLast":"Awaji","presenterInstitution":"University of Nebraska Medical Center","keywords":"Chemokine receptor;Fibroblasts;Fibroblasts;NA","target":"CXCR2","tumor":"Pancreatic","combo":null,"sage":"immunosuppressive","pharma":"academia"},{"id":"5932","name":"5932","title":"Targeting tumor acidity with the LDHA inhibitor (FX11) and CAIX inhibitor (DH348) overcomes resistance to PD-1 blockade and inhibits metastasis in a Pancreatic Cancer model","presenterFirst":"Arig","presenterLast":"Ibrahim Hashim","presenterInstitution":"Moffitt Cancer Center","keywords":"Pancreatic cancer;Metabolism;Metabolism;T cell","target":"LDHA","tumor":"Pancreatic","combo":null,"sage":"immunosuppressive","pharma":"academia"},{"id":"1686","name":"1686","title":"Epigenetic modulation of the tumor microenvironment enhances vaccine induced T cell responses in a murine model of pancreatic cancer","presenterFirst":"Brian","presenterLast":"Christmas","presenterInstitution":"Johns Hopkins University","keywords":"Pancreatic cancer;Epigenetics;Epigenetics;NA","target":"HDAC","tumor":"Pancreatic","combo":null,"sage":"immunosuppressive","pharma":"academia"}]},{"id":"Prostate","name":"Prostate","presenterLast":"Prostate","children":[{"id":"4942","name":"4942","title":"Small molecule inhibition of CXCR4 mobilizes prostate disseminated tumor cells (DTCs) from the chemoprotective bone marrow niche, thereby sensitizing them to chemotherapy","presenterFirst":"Kenneth","presenterLast":"Valkenburg","presenterInstitution":"Johns Hopkins School of Medicine","keywords":"Bone metastasis;Prostate cancer;Prostate cancer;Chemoresistance","target":"CXCR4","tumor":"Prostate","combo":null,"sage":"immunosuppressive","pharma":"academia"},{"id":"3704","name":"3704","title":"Targeting M2-Tumor Associated Macrophages (M2-TAMs) using enriched glycoproteins in Lethal Prostate Cancer","presenterFirst":"Jelani","presenterLast":"Zarif","presenterInstitution":"Johns Hopkins University School of Medicine","keywords":"Macrophages;NA;NA;NA","target":"NA","tumor":"Prostate","combo":null,"sage":"immunosuppressive","pharma":"academia"},{"id":"903","name":"903","title":"CXCR4 and CXCR7 play distinct and overlapping roles in prostate cancer dissemination to bone","presenterFirst":"Sounak","presenterLast":"Roy","presenterInstitution":"Johns Hopkins University","keywords":"Genitourinary cancers: prostate;Bone metastasis;Bone metastasis;Chemokine receptor","target":"CXCR4","tumor":"Prostate","combo":null,"sage":"immunosuppressive","pharma":"academia"}]},{"id":"Sarcoma","name":"Sarcoma","presenterLast":"Sarcoma","children":[{"id":"LB-190","name":"LB-190","title":"Combination of pembrolizumab and metronomic cyclophosphamide in patients with advanced sarcomas: a french sarcoma group study","presenterFirst":"ANTOINE","presenterLast":"ITALIANO","presenterInstitution":"INSTITUT BERGONIE","keywords":"Immunotherapy;NA;NA;NA","target":"chemo","tumor":"Sarcoma","combo":null,"sage":"immunosuppressive","pharma":"academia"}]}]}
